Investment analysts at Stifel Nicolaus started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) in a report issued on Wednesday, Marketbeat.com reports. The brokerage set a "buy" rating and a $45.00 price target on the stock. Stifel Nicolaus' target price would indicate a potential upside of 60.14% from the stock's current price.
PVLA has been the topic of several other research reports. Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an "overweight" rating on the stock. Scotiabank initiated coverage on Palvella Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target on the stock. Canaccord Genuity Group restated a "buy" rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Finally, Jones Trading assumed coverage on shares of Palvella Therapeutics in a report on Tuesday, March 25th. They set a "buy" rating and a $45.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $43.50.
Get Our Latest Analysis on PVLA
Palvella Therapeutics Price Performance
Shares of NASDAQ:PVLA traded up $0.34 during midday trading on Wednesday, reaching $28.10. The company had a trading volume of 74,902 shares, compared to its average volume of 62,262. The stock has a market cap of $315.31 million, a PE ratio of -2.32 and a beta of 0.54. The company's fifty day simple moving average is $20.24. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27.
Institutional Investors Weigh In On Palvella Therapeutics
Several institutional investors have recently bought and sold shares of the stock. BML Capital Management LLC acquired a new position in Palvella Therapeutics during the 4th quarter valued at about $506,000. Geode Capital Management LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter valued at approximately $171,000. ADAR1 Capital Management LLC bought a new stake in Palvella Therapeutics during the fourth quarter worth approximately $1,736,000. Renaissance Technologies LLC acquired a new stake in Palvella Therapeutics in the fourth quarter worth approximately $256,000. Finally, Blue Owl Capital Holdings LP bought a new position in Palvella Therapeutics during the 4th quarter valued at $3,001,000. Institutional investors and hedge funds own 40.11% of the company's stock.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
See Also
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
